ReviewJournal of nanobiotechnology2022
Nanomedicine-enabled chemotherapy-based synergetic cancer treatments.
Review in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- Efficacy and safety of Shenmai injection for acute ischemic stroke: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Nanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced efficacy and reduced toxicity.Nanoscale advances · 2026Review
- NIR-II photothermal-amplified triple catalysis of a spherical mesoporous iron single-atom nanozyme for potentiating ferroptosis-based tumor therapy.Journal of nanobiotechnology · 2026Article
- A Soft Microrobot for Single-Cell Transport, Spheroid Assembly, and Dual-Mode Drug Screening.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Co-encapsulation in Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as an Emerging Therapeutic Strategy.Molecular diagnosis & therapy · 2026Review
- Fraisinib in a Shell: Liposomal Encapsulation of a GARS1 Inhibitor for Controlled Anticancer Delivery.AAPS PharmSciTech · 2026Article
- Kynurenine mediates the chemotherapy-induced intestinal toxicity through modulation of gut microbiota.Nature communications · 2026Article
- Harnessing a cRGD-Targeted Schottky Junction MXene Nanocomposite for Potent Bladder Cancer Therapy: Dual-Modal PTT/PDT Effects with Immune Activation and Favorable Comparison to Doxorubicin.International journal of nanomedicine · 2026Article
- Orchestrating Chemo-Ferroptosis via Nonthermal Magnetocatalysis: A Cascade Amplification Paradigm for Breast Cancer Therapy.Biomaterials research · 2026Article
- Angiogenesis and Related Disorders: Emerging Insights and Future Directions.Biomedicines · 2025Article
- Nano-drug codelivery system of vincristine and gemcitabine loaded hyaluronan-altered hollow mesoporous silica nanoparticles: investigation of in vitro drug release and anticancer activity in pancreatic cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Advances in Second Near-Infrared Window Photothermal Agents and Photothermal Therapy for Tumors in Interdisciplinary Medical Research.Pharmaceutics · 2025Review
- Stealth missiles with precision guidance: A novel multifunctional nano-drug delivery system based on biomimetic cell membrane coating technology.Materials today. Bio · 2025Review
- Reconfigurable Nucleic Acid Nanoparticles with Therapeutic RNAi Responses to Intracellular Disease Markers.Advanced functional materials · 2025Article
- Review
- Immune-related genes can accurately predict survival in bladder cancer: a retrospective study via two independent immunotherapy cohorts.Translational andrology and urology · 2025Article
- Ultra-sensitive pH responsive hydrogels with injectable and self-healing performance for controlled drug delivery.International journal of pharmaceutics: X · 2025Article
- Functionalized chitosan as nano-delivery platform for CRISPR-Cas9 in cancer treatment.Asian journal of pharmaceutical sciences · 2025Review
- CuInternational journal of nanomedicine · 2025Article
- Application of cell-derived vesicle-based biomimetic drug delivery system in tumor therapy.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Chemotherapy remains one of the most prevailing regimens hitherto in the fight against cancer, but its development has been being suffering from various fatal side effects associated with the non-specific toxicity of common chemical drugs. Advances in biomedical application of nanomedicine have been providing alternative but promising approaches for cancer therapy, by leveraging its excellent intrinsic physicochemical properties to address these critical concerns. In particular, nanomedicine-enabled chemotherapy has been established as a safer and promising therapeutic modality, especially the recently proposed nanocatalytic medicine featuring the capabilities to generate toxic substances by initiating diverse catalytic reactions within the tumor without directly relying on highly toxic but non-selective chemotherapeutic agents. Of special note, under exogenous/endogenous stimulations, nanomedicine can serve as a versatile platform that allows additional therapeutic modalities (photothermal therapy (PTT), photodynamic therapy (PDT), chemodynamic therapy (CDT), etc.) to be seamlessly integrated with chemotherapy for efficacious synergistic treatments of tumors. Here, we comprehensively review and summarize the representative studies of multimodal synergistic cancer treatments derived from nanomedicine and nanocatalytic medicine-enabled chemotherapy in recent years, and their underlying mechanisms are also presented in detail. A number of existing challenges and further perspectives for nanomedicine-synergized chemotherapy for malignant solid tumor treatments are also highlighted for understanding this booming research area as comprehensively as possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.